Abiopharma

1Genmab Announces Initiation of Share Buy-Back ProgramCompany AnnouncementRepurchase of up to 370,000 sharesMitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit programCompletion expected on August 31, 2022COPENHAGEN, Denmark June 17, 2022 Genmab AS (Nasdaq GMAB) announced today that it is initiating a share buy-back program to mitigate dilution from warrant exercises and honor our commitments under our Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. Shares acquired under the program cannot be purchased at a price exceeding the higher of (i) the price of.